Adjuvant Atezolizumab plus Bevacizumab vs. Active Surveillance for HCC

Combination therapy with immune checkpoint inhibitors is first line treatment for unresectable or metastatic hepatocellular carcinoma (HCC). After resection or ablation of HCC, there is no proven benefit for adjuvant therapy. Investigators now report interim results from IMbrave50, an open-label, international, industry-sponsored, phase 3 trial evaluating adjuvant treatment with atezolizumab plus bevacizumab in patients with HCC and high risk for recurrence after resection or ablation.

Patients with Child-Pugh class A liver function who had undergone R0 resection or microwave or radiofrequency ablation with complete response were randomized to either active surveillance or one year of treatment with atezolizumab (1200 mg) and bevacizumab (15…